Targets › CD362
1 program from 1 company in 1 trial: 1 Phase 1; Infectious disease.
Open in Phaseline: the race on CD362, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Belfast Health and Social Care Trust | Human umbilical cord derived CD362 enriched MSCs Mesenchymal stem cell therapy with CD362 enrichment | CD362 | Phase 1 | Acute Respiratory Distress Syndrome | – |
Acute Respiratory Distress Syndrome (1)
protein or peptide (1)
Belfast Health and Social Care Trust (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.